Status:
NOT_YET_RECRUITING
Prognostic Prediction Model in Patients With Moyamoya Disease Undergoing Revascularization Surgery
Lead Sponsor:
Beijing Tiantan Hospital
Conditions:
Moyamoya Disease
Eligibility:
All Genders
18+ years
Brief Summary
Moyamoya Disease (MMD) is a rare chronic cerebrovascular disease characterized by progressive occlusion of the internal carotid artery or its major branches, with blood flow compensated by the formati...
Eligibility Criteria
Inclusion
- Age greater than or equal to 18 years.
- Imaging-confirmed moyamoya disease (CTA, CT angiography; MRA, magnetic resonance angiography；DSA, digital subtraction angiography）for MMD patients.
- Selective Revascularization Surgery (direct or indirect);
- Signed informed consent by the patient or legal representative.
Exclusion
- patients with moyamoya syndrome due to an established secondary etiology.
- with severe cardiopulmonary disease that, in the opinion of the investigator, makes them unsuitable for participation in this study.
- patients with a life expectancy of less than 3 months or otherwise unable to complete this study.
- contraindication to DSA examination, severe contrast allergy or absolute contraindication to iodine contrast;
- women of childbearing age who have a negative pregnancy test but refuse to use effective contraception.
- women during pregnancy or breastfeeding.
- those who are unable to complete the study due to psychiatric disorders, cognitive or mood disorders.
- other patients who, in the opinion of the investigator, are not suitable for enrollment in the study (indicate reason).
Key Trial Info
Start Date :
October 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 30 2026
Estimated Enrollment :
350 Patients enrolled
Trial Details
Trial ID
NCT06051552
Start Date
October 1 2023
End Date
September 30 2026
Last Update
September 25 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Capital Medical University, Beijing Tiantan Hospital
Beijing, China